Summary and Analysis of Key Points

Overview:

• ENDRA Life Sciences Inc. is developing a next-generation enhanced ultrasound technology platform called Thermo-Acoustic Enhanced Ultrasound (TAEUS).
• The company’s initial focus is on a solution for assessing liver fat, a key biomarker for metabolic diseases.
• ENDRA plans to offer a subscription-based business model with recurring revenue, while also supporting traditional capital equipment sales.
• In 2025, the company expanded its strategy to include a Digital Asset Treasury (DAT) initiative to optimize capital preservation and generate non-dilutive returns through investments in decentralized finance (DeFi) assets.

Potential Merger:

• On June 25, 2026, ENDRA entered into an agreement to merge with Noble Africa LLC, a subsidiary of ASP Isotopes Inc. that owns Renergen Limited, a South African energy company focused on helium and liquefied natural gas (LNG) production.
• The merger is subject to shareholder approval and other conditions.

Financial Operations Overview:

• ENDRA has not generated any revenue from its TAEUS technology as of June 30, 2026.
• Research and development expenses are the company’s primary costs as it continues to develop the TAEUS platform.
• Sales and marketing expenses have been limited as the company focuses on obtaining regulatory approvals before commercializing the product.
• General and administrative expenses have increased, driven by higher wage and professional fee costs.
• Other income, primarily from changes in the fair value of digital assets and warrant liabilities, has provided a significant boost to the company’s financial results.

Liquidity and Capital Resources:

• As of June 30, 2026, ENDRA had $5.5 million in cash, with $3.8 million restricted.
• The company believes its current cash position is sufficient to fund operations through the anticipated closing of the proposed merger.
• However, without the merger, there is substantial doubt about ENDRA’s ability to continue as a going concern due to its negative cash flows and limited funding options.
• The company may need to raise additional capital through public or private offerings, debt financing, or collaborations to fund future operations and development.

Key Strengths and Weaknesses: Strengths:

• Innovative TAEUS technology platform with potential applications in metabolic disease assessment
• Diversified business strategy including digital asset investments
• Potential benefits from merger with Renergen, including access to helium and LNG resources

Weaknesses:

• No revenue generated from TAEUS technology to date
• Significant ongoing losses and need for additional capital
• Uncertainty around timing and success of regulatory approvals and commercialization

Outlook:

• The proposed merger with Renergen could provide ENDRA with additional resources and strategic opportunities, but its success is not guaranteed.
• Without the merger, ENDRA faces substantial challenges in funding its operations and continuing as a going concern.
• The company’s ability to successfully commercialize its TAEUS technology and generate sustainable revenue will be critical to its long-term viability.